The chemical substance known as "2-Propen-1-one, 1-[4-[5-chloro-6-(2,4-difluoro-5-hydroxyphenyl)-7-fluoro-2,1-benzisothiazol-3-yl]-1-piperazinyl]-" with CAS number 2230873-66-0 is a complex organic compound characterized by its unique structural features. It contains a propenone moiety, which is indicative of its potential reactivity, particularly in Michael addition reactions. The presence of a piperazine ring suggests possible interactions with biological targets, making it of interest in medicinal chemistry. Additionally, the compound features multiple halogen substituents, including chlorine and fluorine atoms, which can enhance its lipophilicity and influence its pharmacokinetic properties. The hydroxyl group on the phenyl ring may contribute to hydrogen bonding capabilities, potentially affecting its solubility and reactivity. Overall, this compound's intricate structure and functional groups suggest it may exhibit significant biological activity, warranting further investigation in pharmaceutical applications.

2-Propen-1-one, 1-[4-[5-chloro-6-(2,4-difluoro-5-hydroxyphenyl)-7-fluoro-2,1-benzisothiazol-3-yl]-1-piperazinyl]-

2230873-66-0: The chemical substance known as "2-Propen-1-one, 1-[4-[5-chloro-6-(2,4-difluoro-5-hydroxyphenyl)-7-fluoro-2,1-benzisothiazol-3-yl]-1-piperazinyl]-" with CAS number 2230873-66-0 is a complex organic compound characterized by its unique structural features. It contains a propenone moiety, which is indicative of its potential reactivity, particularly in Michael addition reactions. The presence of a piperazine ring suggests possible interactions with biological targets, making it of interest in medicinal chemistry. Additionally, the compound features multiple halogen substituents, including chlorine and fluorine atoms, which can enhance its lipophilicity and influence its pharmacokinetic properties. The hydroxyl group on the phenyl ring may contribute to hydrogen bonding capabilities, potentially affecting its solubility and reactivity. Overall, this compound's intricate structure and functional groups suggest it may exhibit significant biological activity, warranting further investigation in pharmaceutical applications.

KRAS inhibitor-18 targets KRAS G12C; IC50: 4.74 μM. Inhibits p-ERK in cancer cells. Promising for pancreatic, colorectal, lung cancer research.

CAS 2230873-66-0

2-Propen-1-one, 1-[4-[5-chloro-6-(2,4-difluoro-5-hydroxyphenyl)-7-fluoro-2,1-benzisothiazol-3-yl]-1-piperazinyl]-

KRAS inhibitor-18

Ref: TM-T62784